FIELD: immunology.
SUBSTANCE: disclosed is a T cell for reducing a tumor burden and/or treating neoplasia comprising a T-cell receptor (TCR) or a chimeric antigen receptor (CAR), which binds to the antigen of B-cell leukemia, and an inhibitory chimeric receptor antigen (iCAR), which contains an intracellular signaling domain CTLA-4 or PD-1. What is also described is the use of such T-cell for reducing tumor load and/or tumor size and pharmaceutical composition. What is also presented is a vector, composition and method for producing T-cells.
EFFECT: use of iCAR enables reducing T-cell cytotoxicity with respect to non-neoplastic tissue cells.
18 cl, 23 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | 2014 |
|
RU2650860C2 |
| HUMANIZED ANTI-PSMA ANTIBODIES | 2019 |
|
RU2794450C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| METHODS OF PRODUCING AND USING GUIDE AND NAVIGATION CONTROL PROTEINS | 2019 |
|
RU2824896C2 |
